Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGWNCJ)

Drug Name

Ifabotuzumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2	[1]
Myelodysplastic syndrome	2A37	Phase 2	[1]
Recurrent glioblastoma	2A00.00	Phase 1	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ephrin type-A receptor 3 (EPHA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KB-004	DM5U3IF	Haematological malignancy	2B33.Y	Phase 1/2	[3]
PMID23489211C20	DMDYC4J	Discovery agent	N.A.	Investigative	[4]
PMID19788238C66	DMCVJK9	Discovery agent	N.A.	Investigative	[5]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of Kalobios.
4	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
5	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
6	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.